Thomasville National Bank Invests $5.49 Million in Merck & Co., Inc. $MRK

Key Points

• Thomasville National Bank acquired 42,746 Merck shares during the second quarter, valued at approximately $5.49 million. Institutional investors collectively own 76.07% of MRK.
• Analysts remain broadly positive, with 15 Buy ratings and seven Holds, producing a consensus “Moderate Buy” rating and an average price target of $135.50. Several firms recently raised their targets to the $141–$150 range.
• Merck reported quarterly revenue of $16.61 billion, ahead of expectations, and declared a quarterly dividend of $0.85 per share. Investors continue to monitor the company’s reliance on Keytruda, future patent-loss risk and recent executive share sales.

Thomasville National Bank acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 42,746 shares of the company's stock, valued at approximately $5,493,000.

A number of other hedge funds also recently made changes to their positions in the stock. Kingdom Financial Group LLC. bought a new stake in Merck & Co., Inc. during the 4th quarter worth approximately $25,000. Abound Financial LLC bought a new position in shares of Merck & Co., Inc. in the fourth quarter worth approximately $26,000. Prosperity Bancshares Inc bought a new position in shares of Merck & Co., Inc. in the fourth quarter worth approximately $26,000. High Note Wealth LLC increased its stake in shares of Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock worth $31,000 after purchasing an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter worth $31,000. 76.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on MRK shares. BMO Capital Markets lifted their target price on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Barclays increased their price target on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. Royal Bank Of Canada reissued an "outperform" rating and set a $142.00 price target on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. Bank of America boosted their price objective on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a "buy" rating in a research report on Tuesday, June 30th. Finally, Guggenheim increased their target price on Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Fifteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $135.50.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrades and higher valuations: Daiwa Securities upgraded Merck to “outperform” with a $143 price target, while other analyst commentary placed fair-value estimates in the $140–$155 range. A separate valuation assessment raised fair value from $132.78 to $136.85, citing pipeline progress and recent business-development activity. Merck fair value article
• Positive Sentiment: Shares reached a record level: Merck was among the companies touching fresh all-time highs, signaling strong recent momentum and investor confidence in its earnings outlook. Merck all-time high article
• Positive Sentiment: Pipeline and core products support growth: Analysts highlighted Merck’s late-stage pipeline, business-development efforts and continued demand for Keytruda. Recent quarterly results also showed revenue of $16.61 billion, above expectations, with oncology and Animal Health cited as important contributors. Merck earnings call analysis
• Neutral Sentiment: Dividend provides income support: Merck declared a quarterly dividend of $0.85 per share, or $3.40 annualized. The payout may support demand for the stock, although the reported payout ratio is elevated.
• Negative Sentiment: Cluster of executive sales: Several executives sold shares, including Jennifer Zachary’s approximately $10.7 million sale, Chirfi Guindo’s $1.35 million sale and Richard Deluca’s additional $1.54 million sale. These transactions reduced their holdings substantially and could weigh modestly on sentiment, though insiders retained shares.
• Negative Sentiment: Keytruda concentration risk: Keytruda remains Merck’s main growth engine, but future patent loss and increasing competition could pressure sales and earnings. Investors will look for newer products and pipeline candidates to offset that risk. Keytruda growth outlook article

Merck & Co., Inc. Price Performance

MRK stock opened at $135.57 on Friday. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The company's fifty day moving average price is $125.25 and its 200-day moving average price is $119.83. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $135.68. The company has a market capitalization of $334.49 billion, a PE ratio of 108.46, a price-to-earnings-growth ratio of 5.73 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. Merck & Co., Inc.'s quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the company posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts anticipate that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.'s payout ratio is 272.00%.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the sale, the executive vice president owned 45,509 shares of the company's stock, valued at $6,073,631.14. The trade was a 63.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Chirfi Guindo sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the sale, the executive vice president directly owned 36,613 shares in the company, valued at $4,942,755. This trade represents a 21.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source